COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prostate Cancer Active Surveillance Metformin Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01733836
Recruitment Status : Withdrawn (The reason for this decision is that this study is being merged with a larger multi-centre study using the same agent in the same population.)
First Posted : November 27, 2012
Last Update Posted : May 24, 2013
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
To determine whether the use of metformin in patients with low-risk prostate cancer can delay progression to clinically significant prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Metformin Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double Blind Placebo Controlled Single Institution Phase 2 Study of Metformin in Patients Undergoing Active Surveillance for Prostate Cancer.
Study Start Date : January 2013
Estimated Primary Completion Date : October 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Metformin
850mg BID
Drug: Metformin
Placebo Comparator: Placebo Drug: placebo

Primary Outcome Measures :
  1. Primary Clinical Outcome - Inhibition of Prostate Cancer [ Time Frame: 18 months ]
    To assess the role of metformin on the inhibition of low-risk localized prostate cancer progression in men undergoing active surveillance for prostate cancer.

  2. Primary Scientific Endpoint - ki67 index [ Time Frame: 18 months ]
    To assess the effect of metformin on the cell cycle proliferation indices (ki67 index).

Secondary Outcome Measures :
  1. Secondary Endpoint - Cell Cycle Proliferation (CCP) Score [ Time Frame: 18 months ]
    To assess the effect of metformin on the cell cycle proliferation indices (CCP score)

  2. Secondary Endpoint - Mechanism of Action [ Time Frame: 18 months ]
    To assess the effect of metformin on systemic and local signalling axes and morphometric measurements relevant to its mechanism of action.

  3. Secondary endpoint - Quality of Life [ Time Frame: 18 months ]
    To assess the impact of metformin on Quality of Life (QoL) indices.

  4. Secondary Endpoint - Prognostic Panel [ Time Frame: 18 months ]
    To determine the utility of a prognostic panel of 31 cell cycle progression genes recently validated in prostate cancer.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to provide informed consent
  • Men >= 18 years of age, and less than 80
  • Men with biopsy proven, low-risk, localized prostate cancer (as defined below)
  • Men choosing expectant management as primary treatment for prostate cancer
  • Diagnostic biopsy performed within 4 months of screening visit
  • Gleason score ≤ 6 in 3 cores or less with no Gleason pattern 4, less than 50% of any core involved in cancer
  • Clinical stage T1c-T2a (Initial diagnosis of T1a/T1b obtained during a TURP is not allowed)
  • Serum PSA ≤10 ng/mL
  • Life expectancy greater than 5 years
  • Normal kidney and hepatic function as defined by the following criteria:

    • Total bilirubin less than 1.5 X institutional upper limit of normal (ULN)
    • AST (SGOT)/ALT(SGPT) less than 1.5 X institutional ULN
    • Alkaline phosphatase less than 2 X institutional ULN
    • Creatinine less than 1.4 X institutional ULN
  • Able to swallow and retain oral medication
  • No exposure to metformin within 12 months of randomization
  • No known hypersensitivity or intolerance to metformin hydrochloride
  • No condition associated with increased risk of metformin hydrochloride-associated lactic acidosis (e.g., congestive heart failure defined as NYHA class III or IV function status, history of acidosis of any type, or habitual intake of ≥ 3 alcoholic beverages per day, or age greater than 80)
  • English fluency allowing for patient reported outcomes completion

Exclusion Criteria:

  • Any previous prostate cancer treatment (radiotherapy, chemotherapy, hormonal therapy, oral glucocorticoids, GnRH analogues)
  • Diabetes including type 1 diabetes. Patients with known type 2 diabetes are eligible provided they have not been on metformin during the previous 12 months and are not on any other pharmacological agents.
  • Concurrent or previous use of anabolic steroids or drugs with anti androgenic properties including 5-ARIs (dutasteride and finasteride)
  • Prostate volume greater than 80 cc. (as per TRUS biopsy report)
  • Prostatic surgery or procedure within 3 months of screening visit
  • Severe BPH symptoms (IPSS ≥25, or ≥20 if already on α-blocker therapy)
  • Other malignancies, with the exception of adequately treated nonmelanoma skin cancer, NMIBC or other solid tumors curatively treated with no evidence of disease for ≥ 5 years
  • Planned or concurrent participation in other interventional randomized trials including exercise
  • The presence of any other coexistent medical condition that in the opinion of the investigator would have the potential to significantly limit adherence to medication, or ability to absorb the medication including but not limited to psychiatric conditions, malabsorption syndromes or severe ischemic heart disease
  • Known hypersensitivity or intolerance to metformin
  • Concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, IGF-1 or their receptors, or PI3K inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01733836

Layout table for location information
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT01733836    
Other Study ID Numbers: MAS_001
First Posted: November 27, 2012    Key Record Dates
Last Update Posted: May 24, 2013
Last Verified: May 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs